Entero Healthcare Solutions Limited (ENTERO) AI Stock Analysis

Top Page

Entero Healthcare Solutions Limited

(NSE:ENTERO)

Select Model

Rating:61Neutral

Price Target:INR 1,923.00▲(22.18% Upside)

Action:reiterated

Date:08/25/26

The score is driven primarily by improving profitability and rapid revenue growth, but weighed down by weak cash conversion/near-zero free cash flow and thin, compressing margins. Technically, the trend is strong with positive momentum, though overbought readings add near-term risk. A high P/E with no dividend yield provided further limits the score.

Positive Factors

Strong Revenue GrowthRapid expansion in revenue shows that Entero is scaling its healthcare distribution network and increasing volumes across pharmacies, hospitals, and institutional customers. Continued growth provides a broader operating base and can support stronger earnings if the company preserves customer reach and execution quality.

Negative Factors

Thin and Compressing MarginsLow and declining margins leave limited room to absorb changes in product mix, pricing, or operating costs. Gross-margin compression from FY2024 to FY2026 also suggests that revenue growth is not fully translating into improved economics, making sustainable profit expansion more difficult.

Entero Healthcare Solutions Limited (ENTERO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 68.56B
Dividend Yield: ―
Average Volume (3M): 39.92K
Price to Earnings (P/E): 54.7
Beta (1Y): 0.62
Revenue Growth: 31.94%
EPS Growth: 22.27%
Country: India
Employees: 4,671
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

Entero Healthcare Solutions Limited Business Overview & Revenue Model

Company Description

Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related product...

How the Company Makes Money

Entero Healthcare Solutions Limited primarily makes money by distributing pharmaceutical and healthcare products: it purchases products from manufacturers and sells them to pharmacies, hospitals, and other healthcare customers, earning a gross margin...

Entero Healthcare Solutions Limited Financial Statement Overview

Summary

Strong revenue scale-up and a clear move from prior-year losses to FY2026 profitability support the score, but distributor-thin margins (gross ~5.9%, net ~1.7%) and margin compression are notable risks. Cash flow quality is the key drag: historically negative operating cash flow until FY2026 and near break-even free cash flow limit confidence in earnings quality and flexibility, while leverage has risen (debt-to-equity ~0.40).

Income Statement

72Positive

Balance Sheet

67Positive

Cash Flow

34Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	71.28B	65.91B	50.96B	39.22B	33.00B	25.15B
Gross Profit	6.01B	3.92B	2.57B	3.48B	2.65B	2.03B
EBITDA	3.18B	2.66B	2.11B	1.26B	694.76M	260.38M
Net Income	1.25B	1.15B	948.20M	391.09M	-115.57M	-299.20M
Balance Sheet
Total Assets	0	36.00B	27.03B	23.45B	13.09B	11.26B
Cash, Cash Equivalents and Short-Term Investments	2.96B	2.92B	3.18B	8.90B	1.07B	1.05B
Total Debt	0	6.77B	4.05B	3.38B	4.38B	3.55B
Total Liabilities	-17.53B	18.48B	9.32B	7.04B	7.76B	5.63B
Stockholders Equity	17.53B	16.89B	17.24B	16.38B	6.23B	5.61B
Cash Flow
Free Cash Flow	-678.96M	17.80M	-916.38M	-420.28M	-508.34M	-451.32M
Operating Cash Flow	-572.73M	693.22M	-803.24M	-366.12M	-453.15M	-352.66M
Investing Cash Flow	-549.08M	-3.17B	1.82B	-7.05B	-485.95M	-1.62B
Financing Cash Flow	-393.12M	1.64B	-320.99M	8.63B	727.64M	2.11B

Entero Healthcare Solutions Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price1573.85

Price Trends

50DMA1682.89Negative

100DMA1451.78Positive

200DMA1307.93Positive

Market Momentum

MACD-40.09Negative

RSI45.95Neutral

STOCH76.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ENTERO, the sentiment is Neutral. The current price of 1573.85 is below the 20-day moving average (MA) of 1596.15, below the 50-day MA of 1682.89, and above the 200-day MA of 1307.93, indicating a neutral trend. The MACD of -40.09 indicates Negative momentum. The RSI at 45.95 is Neutral, neither overbought nor oversold. The STOCH value of 76.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ENTERO.

Entero Healthcare Solutions Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ENTERO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ARTEMISMED	80Outperform	INR 46.26B	38.38	―	0.15%	14.96%	20.76%
IN:BLISSGVS	69Neutral	INR 68.94B	50.66	―	0.23%	20.59%	27.16%
IN:RPGLIFE	62Neutral	INR 42.54B	35.60	―	0.93%	11.78%	-34.54%
IN:ENTERO	61Neutral	INR 68.50B	54.66	―	―	31.94%	22.27%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ORCHPHARMA	54Neutral	INR 49.89B	489.15	―	―	10.83%	-89.83%
IN:UNICHEMLAB	51Neutral	INR 34.04B	11.17	―	―	9.43%	132.94%

* General Sector Average

Performance Comparison

IN:ENTERO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ENTERO	Entero Healthcare Solutions Limited	1573.85	471.70	42.80%
IN:ARTEMISMED	Artemis Medicare Services Ltd.	292.20	47.66	19.49%
IN:BLISSGVS	Bliss Gvs Pharma Limited	648.40	494.04	320.05%
IN:ORCHPHARMA	Orchid Pharma Limited	833.05	64.40	8.38%
IN:RPGLIFE	RPG Life Sciences Limited	2572.40	160.58	6.66%
IN:UNICHEMLAB	Unichem Laboratories Limited	483.45	9.00	1.90%

Entero Healthcare Solutions Limited Corporate Events

Entero Healthcare Subsidiary Pays GST Penalty Under Protest, Plans Refund Claim

Sep 12, 2026

Entero Healthcare Solutions has disclosed that its subsidiary, ACE Cardiopathy Solutions, has been hit with a Goods and Services Tax penalty by the Uttar Pradesh GST Authority for non-generation of an e-invoice. The authority levied a monetary penalt...

Entero Healthcare posts Q1 FY27 earnings call transcript for investors

Aug 17, 2026

Entero Healthcare Solutions Limited has notified stock exchanges that it has made available the transcript of its Q1 FY27 earnings conference call held on August 10, 2026, which discussed the unaudited financial results for the quarter ended June 30,...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 25, 2026

Entero Healthcare Solutions Limited AI Stock Analysis

Top Page